Amicus Therapeutics: A Rare Disease Powerhouse Set to Shine at J.P. Morgan Healthcare Conference
Thursday, Jan 2, 2025 7:19 am ET
FOLD --
Amicus Therapeutics (Nasdaq: FOLD), a global leader in developing and delivering innovative medicines for rare diseases, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Monday, January 13, 2025. The company's President and Chief Executive Officer, Bradley Campbell, will take the stage at 3:00 p.m. PT, providing an update on Amicus' strategic priorities and recent achievements.

Amicus Therapeutics has had an impressive 2023, marked by sustained double-digit growth in Galafold (migalastat) revenue, successful global launches of Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), and the achievement of non-GAAP profitability in the fourth quarter. The company's strong performance is a testament to its commitment to delivering innovative therapies to patients living with rare diseases.
One of the key milestones Amicus Therapeutics is expected to discuss at the conference is the successful launch of Pombiliti + Opfolda, its second commercial therapy for Pompe disease. The company has already treated or scheduled to treat over 120 patients with commercial product in the three largest markets, demonstrating the strong demand for this innovative therapy.

Another significant topic Amicus Therapeutics is likely to cover is its ongoing studies to support medical and scientific leadership in Fabry and Pompe diseases. The company is committed to advancing its pipeline and maintaining its position as a leader in rare disease therapies. This includes supporting clinical trials and registries, such as the global, multicenter, prospective, observational registry of patients with Pompe disease (NCT06121011) and the real-world evidence study of Danish Fabry patients (NCT06303466).
Amicus Therapeutics' focus on rare diseases and innovative therapies has positioned it well for growth and market leadership in the coming years. The company's strong pipeline, global expansion, strategic partnerships, and commitment to patient focus set it apart in the rare disease space. By attending the 43rd Annual J.P. Morgan Healthcare Conference, investors and industry professionals can gain valuable insights into Amicus Therapeutics' strategic priorities and learn about the company's plans to continue driving growth and innovation in the rare disease market.
In conclusion, Amicus Therapeutics' presentation at the 43rd Annual J.P. Morgan Healthcare Conference is an opportunity for investors and industry professionals to learn about the company's recent achievements, strategic priorities, and plans for continued growth and innovation in the rare disease market. With its strong pipeline, global expansion, and commitment to patient focus, Amicus Therapeutics is well-positioned to maintain its competitive edge and continue delivering meaningful benefits to patients living with rare diseases.